LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Chip-Based Technology Enables Direct Detection of Ebolavirus

By LabMedica International staff writers
Posted on 06 Oct 2015
Image: This hybrid device integrates a microfluidic chip for sample preparation and an optofluidic chip for optical detection of individual molecules of viral RNA (Photo courtesy of Joshua W. Parks).
Image: This hybrid device integrates a microfluidic chip for sample preparation and an optofluidic chip for optical detection of individual molecules of viral RNA (Photo courtesy of Joshua W. Parks).
A hybrid device has been developed that integrates a microfluidic chip for sample preparation and an optofluidic chip for optical detection of individual molecules of viral ribonucleic acid (RNA).

The current gold standard for Ebolavirus detection relies on a method called polymerase chain reaction (PCR) to amplify the virus's genetic material for detection. Because PCR works on DNA molecules and Ebola is an RNA virus, the reverse transcriptase enzyme is used to make DNA copies of the viral RNA prior to PCR amplification and detection.

Scientists at The University of California, Santa Cruz (CA, USA) have developed chip-based technology for reliable detection of Ebolavirus and other viral pathogens. The system uses direct optical detection of viral molecules and can be integrated into a simple, portable instrument for use in field situations where rapid, accurate detection of Ebola infections is needed to control outbreaks. The system combines two small chips, a microfluidic chip for sample preparation and an optofluidic chip for optical detection.

The microfluidic devise is made of a silicon-based polymer, polydimethylsiloxane (PDMS), and has microvalves and fluidic channels to transport the sample between nodes for various sample preparation steps. The targeted molecules, in this case, Ebolavirus RNA are isolated by binding to a matching sequence of synthetic DNA, called an oligonucleotide, attached to magnetic microbeads. The microbeads are collected with a magnet, nontarget biomolecules are washed off, and the bound targets are then released by heating, labeled with fluorescent markers, and transferred to the optofluidic chip for optical detection.

In laboratory tests, the system provided sensitive detection of Ebolavirus while giving no positive counts in tests with two related viruses, Sudan ebolavirus and Marburgvirus. Testing with different concentrations of Ebolavirus demonstrated accurate quantification of the virus over six orders of magnitude. Adding a "preconcentration" step during sample processing on the microfluidic chip extended the limit of detection well beyond that achieved by other chip-based approaches, covering a range comparable to PCR analysis.

Holger Schmidt, PhD, a professor of Optoelectronics and senior author of the study, said, “Compared to our system, PCR detection is more complex and requires a laboratory setting. We're detecting the nucleic acids directly, and we achieve a comparable limit of detection to PCR and excellent specificity. The measurements were taken at clinical concentrations covering the entire range of what would be seen in an infected person.” The study was published on September 25, 2015, in the journal Nature Scientific Reports.

Related Links:

The University of California, Santa Cruz  


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Sample Transportation System
Tempus1800 Necto

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more